Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.47391/JPMA.7774 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Parental Experiences of Administering Pediatric for Sleep and Appetite in Early School-Aged Children With Attention-Deficit/Hyperactivity Disorder: Qualitative Study in Hong Kong.
JMIR Pediatr Parent
January 2025
School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China.
Background: Previous research suggested that parent-administered pediatric tuina could improve symptoms of attention-deficit/hyperactivity disorder (ADHD), such as sleep quality and appetite.
Objective: This study aimed to explore the experiences and perceptions of parents administering pediatric tuina to school-aged children with ADHD in Hong Kong.
Methods: This qualitative study was embedded in a pilot randomized controlled trial on parent-administered pediatric tuina for improving sleep and appetite in school-aged children diagnosed with ADHD.
Self-Guided Smartphone App (Vimbo) for the Reduction of Symptoms of Depression and Anxiety in South African Adults: Pilot Quantitative Single-Arm Study.
JMIR Form Res
January 2025
Private Practice, Ballito, South Africa.
Background: Barriers to mental health assessment and intervention have been well documented within South Africa, in both urban and rural settings. Internationally, evidence has emerged for the effectiveness of technology and, specifically, app-based mental health tools and interventions to help overcome some of these barriers. However, research on digital interventions specific to the South African context and mental health is limited.
View Article and Find Full Text PDFClozapine for Treatment-Resistant Disruptive Behaviors in Youths With Autism Spectrum Disorder Aged 10-17 Years: Protocol for an Open-Label Trial.
JMIR Res Protoc
January 2025
Graduate Program of Psychiatry and Behavioral Sciences, Department of Psychiatry, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.
Background: Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition emerging in early childhood, characterized by core features such as sociocommunicative deficits and repetitive, rigid behaviors, interests, and activities. In addition to these, disruptive behaviors (DB), including aggression, self-injury, and severe tantrums, are frequently observed in pediatric patients with ASD. The atypical antipsychotics risperidone and aripiprazole, currently the only Food and Drug Administration-approved treatments for severe DB in patients with ASD, often encounter therapeutic failure or intolerance.
View Article and Find Full Text PDFSyndromic Surveillance and Case Identification for Varicella Among Recent Immigrants: New York City, 2023.
Am J Public Health
January 2025
Melanie S. Askari is with the Epidemic Intelligence Service at the Centers for Disease Control and Prevention (CDC) and the New York City Health Department, Long Island City, NY. Robert J. Arciuolo, Olivia Matalka, Krishika A. Graham, Beth M. Isaac, Ramona Lall, Antonine Jean, and Jennifer B. Rosen are with the New York City Health Department, Bureau of Immunization, Long Island City.
To determine utility of syndromic surveillance in improving varicella case detection during an outbreak among recent immigrants to New York City (NYC). During March through August 2023, the NYC Health Department received varicella reports from routine sources and syndromic surveillance from emergency department visits with varicella as a chief complaint or discharge diagnosis. Reports were reviewed to determine if individuals met criteria for confirmed or probable varicella cases and if cases were outbreak-associated.
View Article and Find Full Text PDFOral Cyclophosphamide for Patients With Metastatic Castration-Resistant Prostate Cancer in a Scenario of Limited Health Care Resources.
JCO Glob Oncol
January 2025
Genitourinary Medical Oncology Service, Instituto do Câncer do Estado de São Paulo (ICESP), University of São Paulo, São Paulo, Brazil.
Purpose: Prior noncontemporary studies showed that oral cyclophosphamide is an active treatment of metastatic castration-resistant prostate cancer (mCRPC). However, cyclophosphamide is currently underutilized in routine clinical practice given the lack of survival benefit and the emergence of more effective treatments.
Methods: We retrospectively reviewed our institutional database to identify patients with mCRPC treated with cyclophosphamide.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!